Tumor cell-secreted angiogenin induces angiogenic activity of endothelial cells by suppressing miR-542-3p

Cancer Letters

Volumn 368, Issue 1, 2015, Pages 115-125

  He, Ting ^a   Qi, Feifei ^a   Jia, Lin ^a   Wang, Shan ^a   Wang, Chunying ^a   Song, Nan ^a   Fu, Yan ^a   Li, Lin ^a   Luo, Yongzhang ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

Angiogenesis; Angiogenin; Breast cancer; MiR 542 3p

Indexed keywords

ANGIOGENIN; MICRORNA; MICRORNA 542 3P; PROTEIN CEBPB; PROTEIN POU2F1; RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; CCAAT ENHANCER BINDING PROTEIN BETA; CEBPB PROTEIN, HUMAN; CONDITIONED MEDIUM; MIRN542 MICRORNA, HUMAN; OCTAMER TRANSCRIPTION FACTOR 1; PANCREATIC RIBONUCLEASE; POU2F1 PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER TISSUE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RNA ANALYSIS; TUMOR CELL; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CONDITIONED MEDIUM; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; NUDE MOUSE; PARACRINE SIGNALING; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE; TUMOR VOLUME; VASCULARIZATION;

ANIMALS; BREAST NEOPLASMS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOVASCULARIZATION, PHYSIOLOGIC; OCTAMER TRANSCRIPTION FACTOR-1; PARACRINE COMMUNICATION; RIBONUCLEASE, PANCREATIC; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR BURDEN;

EID: 84940731772     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.07.036     Document Type: Article

References (59)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
2. Bergers G., Benjamin L.E. Angiogenesis: tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
3. Folkman J. Angiogenesis. Annu. Rev. Med 2006, 57:1-18.
4. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med 2011, 17:1359-1370.
5. Leung D., Cachianes G., Kuang W., Goeddel D., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
6. Ferrara N., Henzel W. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun 1989, 161:851-858.
7. Gao X., Xu Z. Mechanisms of action of angiogenin. Acta Biochim. Biophys. Sin. (Shanghai) 2008, 40:619-624.
8. Ornitz D.M., Itoh N. Fibroblast growth factors. Genome Biol 2001, 2. REVIEWS3005.
9. Eriksson A., Cao R., Pawliuk R., Berg S.M., Tsang M., Zhou D., et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 2002, 1:99-108.
10. Battegay E.J., Rupp J., Iruela-Arispe L., Sage E.H., Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. Journal of Cell Biology 1994, 125:917-928.
11. Fish J., Srivastava D. MicroRNAs: opening a new vein in angiogenesis research. Sci. Signal 2009, 2:pe1.
12. Wang Y., Huang J.W., Castella M., Huntsman D.G., Taniguchi T. p53 is positively regulated by miR-542-3p. Cancer Res 2014, 74:3218-3227.
13. Oneyama C., Morii E., Okuzaki D., Takahashi Y., Ikeda J., Wakabayashi N., et al. MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression. Oncogene 2012, 31:1623-1635.
14. Shen X., Si Y., Yang Z., Wang Q., Yuan J., Zhang X. MicroRNA-542-3p suppresses cell growth of gastric cancer cells via targeting oncogene astrocyte-elevated gene-1. Med. Oncol 2015, 32:361.
15. Formosa A., Lena A.M., Markert E.K., Cortelli S., Miano R., Mauriello A., et al. DNA methylation silences miR-132 in prostate cancer. Oncogene 2013, 32:127-134.
16. Yoon S., Choi Y.C., Lee S., Jeong Y., Yoon J., Baek K. Induction of growth arrest by miR-542-3p that targets survivin. FEBS Lett 2010, 584:4048-4052.
17. Althoff K., Lindner S., Odersky A., Mestdagh P., Beckers A., Karczewski S., et al. miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin. Int. J. Cancer 2015, 136:1308-1320.
18. Moore A.E., Young L.E., Dixon D.A. A common single-nucleotide polymorphism in cyclooxygenase-2 disrupts microRNA-mediated regulation. Oncogene 2012, 31:1592-1598.
19. Qian D.H., Gao P., Feng H., Qin Z.X., Li J.B., Huang L. Down-regulation of mir-542-3p promotes neointimal formation in the aging rat. Vascul. Pharmacol 2015, pii: S1537-1891(15)00112-3.
20. Kureel J., Dixit M., Tyagi A.M., Mansoori M.N., Srivastava K., Raghuvanshi A., et al. miR-542-3p suppresses osteoblast cell proliferation and differentiation, targets BMP-7 signaling and inhibits bone formation. Cell Death Dis 2014, 5:e1050.
21. He T., Qi F., Jia L., Wang S., Song N., Guo L., et al. MicroRNA-542-3p inhibits tumour angiogenesis by targeting angiopoietin-2. J. Pathol 2014, 232:499-508.
22. Shi H., Huang Y., Zhou H., Song X., Yuan S., Fu Y., et al. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 2007, 110:2899-2906.
23. Huang Y., Shi H., Zhou H., Song X., Yuan S., Luo Y. The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood 2006, 107:3564-3571.
24. He Y., Chang G., Zhan S., Song X., Wang X., Luo Y. Soluble tissue factor has unique angiogenic activities that selectively promote migration and differentiation but not proliferation of endothelial cells. Biochem. Biophys. Res. Commun 2008, 370:489-494.
25. Korff T., Augustin H.G. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J. Cell Biol 1998, 143:1341-1352.
26. Ding Y., Huang Y., Song N., Gao X., Yuan S., Wang X., et al. NFAT1 mediates placental growth factor-induced myelomonocytic cell recruitment via the induction of TNF-alpha. J. Immunol 2010, 184:2593-2601.
27. Enerly E., Steinfeld I., Kleivi K., Leivonen S.K., Aure M.R., Russnes H.G., et al. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS ONE 2011, 6:e16915.
28. Kishimoto K., Liu S., Tsuji T., Olson K.A., Hu G.F. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 2005, 24:445-456.
29. Moroianu J., Riordan J.F. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:1677-1681.
30. Schmeier S., MacPherson C.R., Essack M., Kaur M., Schaefer U., Suzuki H., et al. Deciphering the transcriptional circuitry of microRNA genes expressed during human monocytic differentiation. BMC Genomics 2009, 10:595.
31. Ström A., Forsberg M., Lillhager P., Westin G. The transcription factors Sp1 and Oct-1 interact physically to regulate human U2 snRNA gene expression. Nucleic Acids Res 1996, 24:1981-1986.
32. Pau Ni I.B., Zakaria Z., Muhammad R., Abdullah N., Ibrahim N., Aina Emran N., et al. Gene expression patterns distinguish breast carcinomas from normal breast tissues: the Malaysian context. Pathol. Res. Pract 2010, 206:223-228.
33. Fett J.W., Strydom D.J., Lobb R.R., Alderman E.M., Bethune J.L., Riordan J.F., et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 1985, 24:5480-5486.
34. Montero S., Guzman C., Cortes-Funes H., Colomer R. Angiogenin expression and prognosis in primary breast carcinoma. Clin. Cancer Res 1998, 4:2161-2168.
35. Katona T.M., Neubauer B.L., Iversen P.W., Zhang S., Baldridge L.A., Cheng L. Elevated expression of angiogenin in prostate cancer and its precursors. Clin. Cancer Res 2005, 11:8358-8363.
36. Hisai H., Kato J., Kobune M., Murakami T., Miyanishi K., Takahashi M., et al. Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. Clin. Cancer Res 2003, 9:4852-4859.
37. Shimoyama S., Yamasaki K., Kawahara M., Kaminishi M. Increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression. Clin. Cancer Res 1999, 5:1125-1130.
38. Hartmann A., Kunz M., Kostlin S., Gillitzer R., Toksoy A., Brocker E.B., et al. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 1999, 59:1578-1583.
39. Shimoyama S., Gansauge F., Gansauge S., Negri G., Oohara T., Beger H.G. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res 1996, 56:2703-2706.
40. Urquidi V., Goodison S., Cai Y., Sun Y., Rosser C.J. A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol. Biomarkers Prev 2012, 21:2149-2158.
41. Miyake H., Hara I., Yamanaka K., Gohji K., Arakawa S., Kamidono S. Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence. Cancer 1999, 86:316-324.
42. Barton D.P., Cai A., Wendt K., Young M., Gamero A., De Cesare S. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin. Cancer Res 1997, 3:1579-1586.
43. Tsuji T., Sun Y., Kishimoto K., Olson K.A., Liu S., Hirukawa S., et al. Angiogenin is translocated to the nucleus of HeLa cells and is involved in ribosomal RNA transcription and cell proliferation. Cancer Res 2005, 65:1352-1360.
44. Miyake M., Goodison S., Lawton A., Gomes-Giacoia E., Rosser C.J. Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway. Oncogene 2015, 34(7):890-901.
45. Nilsson U.W., Abrahamsson A., Dabrosin C. Angiogenin regulation by estradiol in breast tissue: tamoxifen inhibits angiogenin nuclear translocation and antiangiogenin therapy reduces breast cancer growth in vivo. Clin. Cancer Res 2010, 16:3659-3669.
46. Piccoli R., Olson K.A., Vallee B.L., Fett J.W. Chimeric anti-angiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenografts in athymic mice. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:4579-4583.
47. Olson K.A., Fett J.W., French T.C., Key M.E., Vallee B.L. Angiogenin antagonists prevent tumor growth in vivo. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:442-446.
48. Zhao H., Grossman H.B., Delclos G.L., Hwang L.Y., Troisi C.L., Chamberlain R.M., et al. Increased plasma levels of angiogenin and the risk of bladder carcinoma: from initiation ot recurrence. Cancer 2005, 104:30-35.
49. Vihinen P., Kallioinen M., Vuoristo M.S., Ivaska J., Syrjanen K.J., Hahka-Kemppinen M., et al. Serum angiogenin levels predict treatment response in patients with stage IV melanoma. Clin. Exp. Metastasis 2007, 24:567-574.
50. Passam F.H., Sfiridaki A., Pappa C., Kyriakou D., Petreli E., Roussou P.A., et al. Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment. Int. J. Lab. Hematol 2008, 30:17-25.
51. Pina F., Botelho F., Lopes T., Lopes I., Figueiredo G., Portugal R., et al. Can serum angiogenin be used to improve the diagnostic performance in prostate cancer screening?. Eur. J. Cancer Prev 2014, 23:166-172.
52. Robinson G.W., Johnson P.F., Hennighausen L., Sterneck E. The C/EBPbeta transcription factor regulates epithelial cell proliferation and differentiation in the mammary gland. Genes Dev 1998, 12:1907-1916.
53. Zahnow C.A. CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev. Mol. Med 2009, 11:e12.
54. Johansson J., Berg T., Kurzejamska E., Pang M.F., Tabor V., Jansson M., et al. MiR-155-mediated loss of C/EBPbeta shifts the TGF-beta response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene 2013, 32:5614-5624.
55. Uhlen M., Bjorling E., Agaton C., Szigyarto C.A., Amini B., Andersen E., et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell. Proteom 2005, 4:1920-1932.
56. Kurzejamska E., Johansson J., Jirstrom K., Prakash V., Ananthaseshan S., Boon L., et al. C/EBPbeta expression is an independent predictor of overall survival in breast cancer patients by MHCII/CD4-dependent mechanism of metastasis formation. Oncogenesis 2014, 3:e125.
57. Rhodes D.R., Kalyana-Sundaram S., Mahavisno V., Varambally R., Yu J., Briggs B.B., et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007, 9:166-180.
58. Zhao H., Jin S., Fan F., Fan W., Tong T., Zhan Q. Activation of the transcription factor Oct-1 in response to DNA damage. Cancer Res 2000, 60:6276-6280.
59. Fan W., Jin S., Tong T., Zhao H., Fan F., Antinore M.J., et al. BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs. J. Biol. Chem 2002, 277:8061-8067.